PT94064A - Processo para a preparacao de novos conjugados de antraciclina que comportam um novo ligante e de composicoes farmaceuticas que os contem - Google Patents
Processo para a preparacao de novos conjugados de antraciclina que comportam um novo ligante e de composicoes farmaceuticas que os contemInfo
- Publication number
- PT94064A PT94064A PT94064A PT9406490A PT94064A PT 94064 A PT94064 A PT 94064A PT 94064 A PT94064 A PT 94064A PT 9406490 A PT9406490 A PT 9406490A PT 94064 A PT94064 A PT 94064A
- Authority
- PT
- Portugal
- Prior art keywords
- anthracycline
- conjugates
- ligand
- pharmaceutical compositions
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/353,729 US5122368A (en) | 1988-02-11 | 1989-05-17 | Anthracycline conjugates having a novel linker and methods for their production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT94064A true PT94064A (pt) | 1991-01-08 |
| PT94064B PT94064B (pt) | 1997-07-31 |
Family
ID=23390328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT94064A PT94064B (pt) | 1989-05-17 | 1990-05-16 | Processo para a preparacao de novos conjugados de antraciclina que comportam um novo ligante e de composicoes farmaceuticas que os contem |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0398305B1 (pt) |
| JP (1) | JP3062696B2 (pt) |
| KR (1) | KR0136899B1 (pt) |
| AT (1) | ATE150321T1 (pt) |
| AU (1) | AU631638B2 (pt) |
| CA (1) | CA2016584C (pt) |
| DE (1) | DE69030213T2 (pt) |
| DK (1) | DK0398305T3 (pt) |
| ES (1) | ES2099075T3 (pt) |
| FI (1) | FI102356B1 (pt) |
| GR (1) | GR3023784T3 (pt) |
| HK (1) | HK1005018A1 (pt) |
| IE (1) | IE81109B1 (pt) |
| IL (1) | IL94379A (pt) |
| MY (1) | MY131039A (pt) |
| NO (1) | NO300691B1 (pt) |
| NZ (1) | NZ233696A (pt) |
| PT (1) | PT94064B (pt) |
| ZA (1) | ZA903757B (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU638971B2 (en) * | 1990-02-14 | 1993-07-15 | Bristol-Myers Squibb Company | Anthracycline immunoconjugates having a novel linker and methods for their production |
| CA2048089A1 (en) * | 1990-09-17 | 1992-03-18 | Wolfgang A. Wrasidlo | Chemical conjugation of morpholino anthracyclines to antibodies |
| US5622929A (en) * | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| RU2119354C1 (ru) * | 1996-01-05 | 1998-09-27 | Виктор Савельевич Гуревич | Способ направленного транспорта фармакологических препаратов путем их конъюгации с аргинил-глицил-аспартил (rgd) содержащими пептидами |
| US7033765B1 (en) | 1997-02-20 | 2006-04-25 | Toronto Research Chemicals, Inc. | Site-specific drug delivery |
| DE69830305T2 (de) * | 1997-02-20 | 2006-02-02 | Dime, David S., Toronto | Ortsspezifische arzneimittel verabreichung |
| GB9724838D0 (en) * | 1997-11-26 | 1998-01-21 | Franks Christopher R | Compositions |
| JP2004501171A (ja) * | 2000-06-28 | 2004-01-15 | フォーク ワード ページ | A)臓器が移植された患者における活性化されたリンパ球への、b)放射線療法を受ける患者における、癌細胞への放射線増感剤としての、c)癌の診断および治療における薬物担体としてのビタミン結合タンパク質中の、細胞毒の標的指向型送達 |
| AU2002216864A1 (en) * | 2000-12-21 | 2002-07-01 | Mcgill University | Conjugates of antibodies and anticancer drugs |
| NZ511705A (en) * | 2001-05-14 | 2004-03-26 | Horticulture & Food Res Inst | Methods and rapid immunoassay device for detecting progesterone and other steroids |
| KR100507968B1 (ko) * | 2001-08-18 | 2005-08-17 | 한국과학기술연구원 | 자기집합체를 형성하는 항암제-키토산 복합체 및 그의제조방법 |
| RU2361876C2 (ru) | 2003-04-22 | 2009-07-20 | Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик С.А.С. | Пептидные векторы |
| EP1680073B1 (en) | 2003-10-21 | 2013-01-02 | IGF Oncology, LLC | Compounds and method for treating cancer |
| US9011880B2 (en) | 2003-10-21 | 2015-04-21 | Igf Oncology, Llc | Compounds and methods for treating cancer |
| WO2005084390A2 (en) * | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| EP1695717A1 (en) * | 2005-02-23 | 2006-08-30 | Ludwig-Maximilians-Universität | Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells |
| MX2011000509A (es) | 2008-07-15 | 2011-04-05 | Genentech Inc | Conjugados derivados de antraciclina, proceso para su preparacion y su uso como compuestos antitumorales. |
| CA2936675C (en) | 2014-01-12 | 2023-06-27 | Igf Oncology, Llc | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof |
| JP6622293B2 (ja) * | 2014-09-12 | 2019-12-18 | ジェネンテック, インコーポレイテッド | アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法 |
| CN110636867B (zh) | 2017-05-21 | 2023-09-05 | Igf肿瘤公司 | 胰岛素样生长因子——用于治疗骨髓增生异常综合症的化学治疗缀合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3957755A (en) * | 1967-10-18 | 1976-05-18 | Rhone-Poulenc S.A. | Naphthacene derivatives |
| US4112217A (en) * | 1977-09-02 | 1978-09-05 | Sri International | Bis-hydrazones of daunomycin and adriamycin |
| US4263428A (en) * | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| US5162512A (en) * | 1982-03-09 | 1992-11-10 | Cytogen Corporation | Amine derivatives of anthracycline antibodies |
| US4950738A (en) * | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
| GB8610551D0 (en) * | 1986-04-30 | 1986-06-04 | Hoffmann La Roche | Polypeptide & protein derivatives |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| AU638971B2 (en) * | 1990-02-14 | 1993-07-15 | Bristol-Myers Squibb Company | Anthracycline immunoconjugates having a novel linker and methods for their production |
-
1990
- 1990-05-11 CA CA002016584A patent/CA2016584C/en not_active Expired - Lifetime
- 1990-05-14 FI FI902387A patent/FI102356B1/fi active IP Right Grant
- 1990-05-14 IL IL9437990A patent/IL94379A/xx not_active IP Right Cessation
- 1990-05-15 NZ NZ233696A patent/NZ233696A/en unknown
- 1990-05-16 ZA ZA903757A patent/ZA903757B/xx unknown
- 1990-05-16 ES ES90109268T patent/ES2099075T3/es not_active Expired - Lifetime
- 1990-05-16 NO NO902197A patent/NO300691B1/no not_active IP Right Cessation
- 1990-05-16 DE DE69030213T patent/DE69030213T2/de not_active Expired - Lifetime
- 1990-05-16 IE IE176490A patent/IE81109B1/en not_active IP Right Cessation
- 1990-05-16 AU AU55117/90A patent/AU631638B2/en not_active Expired
- 1990-05-16 PT PT94064A patent/PT94064B/pt not_active IP Right Cessation
- 1990-05-16 EP EP90109268A patent/EP0398305B1/en not_active Expired - Lifetime
- 1990-05-16 DK DK90109268.4T patent/DK0398305T3/da active
- 1990-05-16 AT AT90109268T patent/ATE150321T1/de not_active IP Right Cessation
- 1990-05-17 KR KR1019900007085A patent/KR0136899B1/ko not_active Expired - Fee Related
- 1990-05-17 JP JP2125629A patent/JP3062696B2/ja not_active Expired - Lifetime
- 1990-05-17 MY MYPI90000790A patent/MY131039A/en unknown
-
1997
- 1997-06-13 GR GR970401423T patent/GR3023784T3/el unknown
-
1998
- 1998-05-15 HK HK98104210A patent/HK1005018A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR900017597A (ko) | 1990-12-19 |
| FI102356B (fi) | 1998-11-30 |
| ATE150321T1 (de) | 1997-04-15 |
| IE81109B1 (en) | 2000-03-08 |
| NO300691B1 (no) | 1997-07-07 |
| EP0398305B1 (en) | 1997-03-19 |
| PT94064B (pt) | 1997-07-31 |
| DE69030213T2 (de) | 1997-10-16 |
| CA2016584A1 (en) | 1990-11-17 |
| KR0136899B1 (ko) | 1998-04-25 |
| AU631638B2 (en) | 1992-12-03 |
| ES2099075T3 (es) | 1997-05-16 |
| DE69030213D1 (de) | 1997-04-24 |
| DK0398305T3 (da) | 1997-06-23 |
| JPH0327321A (ja) | 1991-02-05 |
| AU5511790A (en) | 1990-11-22 |
| EP0398305A3 (en) | 1991-03-20 |
| IL94379A0 (en) | 1991-03-10 |
| FI102356B1 (fi) | 1998-11-30 |
| CA2016584C (en) | 1999-06-29 |
| NZ233696A (en) | 1992-04-28 |
| NO902197D0 (no) | 1990-05-16 |
| IE901764L (en) | 1990-11-17 |
| IL94379A (en) | 1997-02-18 |
| HK1005018A1 (en) | 1998-12-18 |
| EP0398305A2 (en) | 1990-11-22 |
| ZA903757B (en) | 1992-01-29 |
| NO902197L (no) | 1990-11-19 |
| MY131039A (en) | 2007-07-31 |
| FI902387A0 (fi) | 1990-05-14 |
| GR3023784T3 (en) | 1997-09-30 |
| JP3062696B2 (ja) | 2000-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT94064A (pt) | Processo para a preparacao de novos conjugados de antraciclina que comportam um novo ligante e de composicoes farmaceuticas que os contem | |
| PT89683A (pt) | Processo para a preparacao de imunoconjugados de antraciclina comportando novos ligandos | |
| PT101702A (pt) | Processo para a preparacao de profarmacos antraciclinicos e de composicoes e de associacoes farmaceuticas que os contem ligados a conjugados anticorpo-benzima | |
| PT97639A (pt) | Processo para a preparacao de hidrazinas n-substituidas bifuncionais e de composicoes farmaceuticas que as contem | |
| Beitz et al. | Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo | |
| PT730608E (pt) | Composicoes compreendendo hidratos de carbono e proeinas relacionadas pelo complemento e metodos para produzir e utilizar as referidas composicoes | |
| JPH0639387B2 (ja) | 免疫毒素複合体 | |
| HU9302517D0 (en) | Pharmaceutical compositions containing antracyclin glycosides bound with polymers and process for producing them | |
| WO1993025228A1 (en) | Cytotoxins specific for gm-csf receptor-bearing cells | |
| CA2010164A1 (en) | Anthracycline immunoconjugates having a novel linker and methods for their production | |
| RU95105590A (ru) | Гепатотропные конъюгаты антивирусных лекарственных средств, их носители, содержащие их фармацевтические композиции, способ получения конъюгатов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG3A | Patent granted, date of granting |
Effective date: 19970430 |
|
| MM4A | Annulment/lapse due to non-payment of fees, searched and examined patent |
Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20111031 |
|
| MM4A | Annulment/lapse due to non-payment of fees, searched and examined patent |
Free format text: MAXIMUM VALIDITY LIMIT REACHED Effective date: 20120430 |